# Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma

> **NCT03526679** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Taiwan University Hospital** · enrollment: 30 (actual)

## Conditions studied

- Leiomyosarcoma
- Liposarcoma
- Soft Tissue Sarcoma Adult
- Advanced Cancer

## Interventions

- **DRUG:** Eribulin
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT03526679
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-12
- **Primary completion:** 2021-06-30
- **Final completion:** 2025-10-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03526679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03526679, "Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03526679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*